clonidine has been researched along with Atherosclerotic Parkinsonism in 6 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purported alpha 2-adrenergic agonist clonidine was found to inhibit rest tremor at doses of 0." | 7.68 | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B, 1991) |
| "The purported alpha 2-adrenergic agonist clonidine was found to inhibit rest tremor at doses of 0." | 3.68 | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balldin, J | 1 |
| Granérus, AK | 1 |
| Lindstedt, G | 1 |
| Modigh, K | 1 |
| Wålinder, J | 1 |
| Henry, B | 1 |
| Crossman, AR | 1 |
| Brotchie, JM | 2 |
| Hill, MP | 1 |
| Silvestrini, B | 1 |
| Lisciani, R | 1 |
| Svensson, A | 1 |
| Carlsson, ML | 1 |
| Gomez-Mancilla, B | 1 |
| Boucher, R | 1 |
| Bédard, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo Controlled Study of Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease[NCT00029666] | Phase 2 | 40 participants | Interventional | 2002-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for clonidine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Neuroendocrine evidence for increased responsiveness of dopamine receptors in humans following electroconvulsive therapy.
Topics: Adult; Aged; Apomorphine; Clonidine; Depressive Disorder; Electroconvulsive Therapy; Female; Growth | 1982 |
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Behavior, An | 1998 |
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzofurans; | 1999 |
Experimental data suggesting an adrenergic mechanism in the production of parkinsonian symptoms.
Topics: 5-Hydroxytryptophan; Animals; Atropine; Clonidine; Female; Fenclonine; Imipramine; Male; Mice; Mice, | 1976 |
Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induces pronounced locomotor stimulation.
Topics: 2-Amino-5-phosphonovalerate; Animals; Biogenic Monoamines; Clonidine; Disease Models, Animal; Drug S | 1992 |
Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Atropine; Clonidine; Disease Models, Animal; | 1991 |